Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib maintenance in resected head and neck cancer
NCT00412217Phase 3Terminated
- Sponsor
- Roche
- Start
- Nov 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Erlotinib with Placebo (2 arms). Primary endpoints: Number of Participants With Disease Progression up to 3 years and Time to Progression up to 3 years. Started Nov 2006; status: terminated.
02
Drugs
erlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00412217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412217.